Radiopharm Theranostics (RADX): SEC Form 3 filed by new insider Voliotis Dimitris
Stocks in this Quantisnow insightHealth Care
Historical context for RADX
Across the 15 sessions after earlier RADX headlines, the stock closed higher 7 times and lower 6 times, with a median move of 2.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | RADX | SPY |
|---|---|---|---|
| Apr 23, 2026 | Radiopharm Theranostics Reports Business Update | -2.5% | -0.4% |
| Apr 20, 2026 | Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 | +4.6% | -0.2% |
| Apr 16, 2026 | Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases | -0.2% | +0.2% |
| Apr 8, 2026 | Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial | +3.0% | +2.5% |
| Apr 7, 2026 | Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. | -1.6% | +0.0% |
| Mar 27, 2026 | Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer | +0.0% | -1.7% |
Quantisnow market dataNASDAQ
RADX
Radiopharm Theranostics Limited
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for RADX
Full RADX profile on Quantisnow Follow RADX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time